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Abstract
Background: The combinatorial library strategy of using multiple candidate ligands in mixtures as library members
is ideal in terms of cost and efficiency, but needs special screening methods to estimate the affinities of candidate
ligands in such mixtures. Herein, a new method to screen candidate ligands present in unknown molar quantities
in mixtures was investigated.
Results: The proposed method involves preparing a processed-mixture-for-screening (PMFS) with each mixture
sample and an exogenous reference ligand, initiating competitive binding among ligands from the PMFS to a
target immobilized on magnetic particles, recovering target-ligand complexes in equilibrium by magnetic force,
extracting and concentrating bound ligands, and analyzing ligands in the PMFS and the concentrated extract by
chromatography. The relative affinity of each candidate ligand to its reference ligand is estimated via an
approximation equation assuming (a) the candidate ligand and its reference ligand bind to the same site(s) on the
target, (b) their chromatographic peak areas are over five times their intercepts of linear response but within their
linear ranges, (c) their binding ratios are below 10%. These prerequisites are met by optimizing primarily the
quantity of the target used and the PMFS composition ratio.
The new method was tested using the competitive binding of biotin derivatives from mixtures to streptavidin
immobilized on magnetic particles as a model. Each mixture sample containing a limited number of candidate
biotin derivatives with moderate differences in their molar quantities were prepared via parallel-combinatorial-
synthesis (PCS) without purification, or via the pooling of individual compounds. Some purified biotin derivatives
were used as reference ligands. This method showed resistance to variations in chromatographic quantification
sensitivity and concentration ratios; optimized conditions to validate the approximation equation could be applied
to different mixture samples. Relative affinities of candidate biotin derivatives with unknown molar quantities in
each mixture sample were consistent with those estimated by a homogenous method using their purified
counterparts as samples.
Conclusions: This new method is robust and effective for each mixture possessing a limited number of candidate
ligands whose molar quantities have moderate differences, and its integration with PCS has promise to routinely
practice the mixture-based library strategy.
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Ligands of proteins are widely used as clinical drugs,
and as research and analytical tools. To discover valu-
able ligands that possess strong affinities to a desired
binding site on a protein target, the combinatorial
library strategy is a powerful method, but it is usually
thwarted by the cost and time involved in preparing and
screening library members [1-9]. In theory, an ideal
approach to the combinatorial library strategy would
integrate the preparation of multiple candidate ligands
in each mixture as a library member with the simulta-
neous estimation of affinities and the concurrent judg-
ment of binding site(s) of all candidate ligands in the
mixture as a sample. This integration approach belongs
to the mixture-based library strategy, and may have pro-
nounced advantages to discover valuable optically-active
ligands because it is easy to prepare racemic reaction
mixtures instead of optically-pure enantiomers as library
members [3,4,6,9].
Nowadays, to practice the mixture-based library strat-
egy, mixtures of multiple candidate ligands are routinely
prepared via the pooling of individual compounds, paral-
lel combinatorial synthesis (PCS) or the fractionation of
crude extracts of natural products. The preparation of
mixtures of multiple candidate ligands via the pooling of
individual compounds suffers from the cost and time
required for synthesizing individual compounds, but the
composition ratios of candidate ligands in these mixtures
can be rigorously controlled. The preparation of mixtures
of multiple candidate ligands via PCS or the fractionation
of crude extracts of natural products has attractive cost
and efficiency. However, the composition ratios of candi-
date ligands in these mixtures cannot be rigorously con-
trolled when PCS is utilized, while such composition
ratios can hardly be controlled at all when the fractiona-
tion of crude extracts of natural products is used.
Currently, high-throughput-screening techniques are
commonly used to quantify affinities of candidate ligands
from libraries, but they require individual compounds
with purities of over 80%, rather than mixtures of com-
pounds, as library members [1,2,5,8,9]. To concurrently
estimate the affinities of multiple candidate ligands in the
aforementioned mixtures, several screening methods are
available as discussed below; however, they all suffer
some disadvantages. (a) The frontal-affinity-chromato-
graphy technique has ideal efficiency, but requires affinity
columns of short life-times and exhibits low reliability to
judge the binding site(s) of multiple candidate ligands of
unknown concentration in a mixture under analysis
[10,11]. (b) The size-exclusion-chromatography affinity-
selection mass-spectrometry technique measures the affi-
nities of multiple candidate ligands in a mixture, but
requires special instrumentation and is inapplicable to
multiple candidate ligands of unknown concentration in
a mixture [11-15]. (c) High-performance-liquid-chroma-
tography mass-spectrometry (HPLC-MS) coupled to
ultra-filtration determines the affinities of multiple candi-
date ligands of unknown concentration in a mixture, but
requires protein targets of high thermostability and exhi-
bits too low efficiency [13,16,17]. (d) Indirect deconvolu-
tion techniques show favorable efficiency in the
screening of thousands of candidate ligands of unknown
concentration in a mixture, but rely on synthetic reac-
tions of rigorous yields and accurate assays of activities of
ligand mixtures [18-21]. (e) Direct deconvolution techni-
ques are very efficient for screening multiple candidate
ligands of unknown concentration in a mixture, but the
design, preparation and analysis of the chemical tags for
coding candidate ligands in each mixture is quite challen-
ging [18-21]. (f) The diffusion-based method measures
the affinities of multiple candidate ligands in mixtures,
but is applicable mainly to candidate ligands of known
concentration in a mixture [22]. Hence, new methods are
needed to screen multiple candidate ligands of unknown
concentration in mixture samples.
In general, to simultaneously quantify affinities of
multiple candidate ligands in a mixture, both the separa-
tion of the target-ligand complexes from free ligands
and chromatographic analyses of ligand mixtures are
required. It is known that target-ligand complexes can
be readily recovered via magnetic force with satisfactory
recovery ratios and practical efficiency as long as protein
targets are immobilized on magnetic particles [23-29].
Thus far, however, the magnetic recovery of target-
ligand complexes coupled to chromatographic analyses
of ligand mixtures has failed to quantify affinity(ies) of
candidate ligand(s) in mixtures [26-29]. Therefore, based
on the magnetic recovery of target-ligand complexes
and chromatographic analyses of ligand mixtures, we
report here a new method to estimate the affinities of a
limited number of candidate ligands possessing moder-
ate differences in their molar quantities in each mixture
as a sample. Chemometrics to approximate ligand affi-
nities and strategies to optimize principal factors are
proposed, and their effectiveness has been tested with
competitive binding of biotin derivatives in mixtures to
streptavidin immobilized on magnetic nanoparticles
(SMPP) as a model.
Results
Chemometrics to estimate affinities of candidate ligands
in a mixture
By employing an exogenous reference ligand to each
mixture sample, this new method utilizes the basic steps
shown in Figure 1, and is distinctively characterized by
the preparation of a processed-mixture-for-screening
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ligand. In practice, such a PMFS and the target immobi-
lized on magnetic particles are mixed to initiate compe-
titive binding; target-ligand complexes in equilibrium
are recovered via magnetic force; bound ligands are
extracted with suitable solvent(s) and concentrated
according to a preset concentration ratio. Then, candi-
date ligand(s) and the reference ligand in both the
PMFS and its concentrated extract are quantified using
a chromatographic system under identical conditions
(the volumes of solutions loaded for chromatographic
analyses are kept constant). Finally, the relative affinity
of each candidate ligand, which is quantifiable together
with the reference ligand in the PMFS and its concen-
trated extract, is approximated via Eq.(6) as described
below.
To derive Eq.(6), the following parameters are
defined for a pair of a candidate ligand and its refer-
ence ligand.
ATA: peak area for the reference ligand in a competi-
tive binding system, which is determined directly
with the PMFS after proper dilution;
ATX: peak area for a quantifiable candidate ligand in
a competitive binding system, which is determined
directly with the PMFS after proper dilution;
ABA: peak area for the bound reference ligand in the
concentrated extract from the competitive binding
system;
ABX: peak area for the bound candidate ligand in the
concentrated extract from the competitive binding
system;
NFS: the quantity of total unoccupied binding site(s)
on the protein target used in the competitive binding
system;
CR: the ratio of the volume of the competitive bind-
ing system to the volume of the concentrated extract
of bound ligands to be analyzed by a chromato-
graphic system;
KA: the equilibrium constant for the binding of the
reference ligand to the target;
KX: the equilibrium constant for the binding of the
candidate ligand to the target;
RRA: the overall recovery ratio of the reference
ligand after the whole operation process;
RRX: the overall recovery ratio of the candidate
ligand after the whole operation process;
BRA: the binding ratio of the reference ligand in the
competitive binding system;
BRX: the binding ratio of the candidate ligand in the
competitive binding system;
The reference ligand and the candidate ligands, which
are simultaneously quantifiable using a chromatographic
system, are referred to as ligands of interest hereafter.
The linear response of chromatographic peak areas of
any resolved component to its quantities loaded for ana-
lyses yields a slope, an intercept and a linear range. If
each ligand of interest, in both the PMFS and the con-
centrated extract, produces peak areas within the linear
range but over five times the absolute value of the inter-
cept of linear response, the intercept can be neglected
to derive the quantities of the ligand of interest under
analyses from the peak areas. In this case, Eq.(1) and
Eq.(2) approximate the binding equilibrium constants
for the reference ligand and the candidate ligand,
Figure 1 Basic operation steps to realize this new method.
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Page 3 of 18respectively, while Eq.(3) and Eq.(4) approximate their
corresponding binding ratios.
KA ≈
ABA

(RRA × CR)
(ATA − ABA

(RRA × CR)) × NFS
(1)
KX ≈
ABX

(RRX × CR)
(ATX − ABX

(RRX × CR)) × NFS
(2)
BRA ≈
ABA

CR
ATA × RRA
(3)
BRX ≈
ABX

CR
ATX × RRX
(4)
The relative affinity of the candidate ligand to the
reference ligand is defined as Kx/KA. In Eq.(1) and Eq.
(2), CR is the same for the reference ligand and the can-
didate ligand because they co-exist in both the same
concentrated extract of bound ligands and the same
competitive binding system. If the candidate ligand and
the reference ligand in the PMFS bind to the same site
(s) on the target, NFS i st h es a m ei nE q . ( 1 )a n dE q . ( 2 ) ,
and thus Eq.(5) applies.
KX
KA
≈
ATA − ABA

(RRA × CR)
ATX − ABX

(RRX × CR)
×
ABX × RRA
ABA × RRX
(5)
RRAa n dRRx are determined concurrently with a
PMFS or any similar mixture of the reference ligand
and the candidate ligand. When the binding ratios of
the reference ligand and the candidate ligand are below
10%, ABA/(RRA× CR)a n dABX/(RRx/CR) are negligible
in comparison to ATA and ATX [30], respectively, and
thus Eq.(6) applies.
KX
KA
≈

RRA
RRX

×

ABX
ABA

ATX
ATA

(6)
Clearly, the reliability of the relative affinity of a candi-
date ligand relies on the validity of Eq.(6), and requires
the simultaneous satisfaction of the following prerequi-
sites for the pair of the candidate ligand and its refer-
ence ligand. (a) The candidate ligand and its reference
ligand bind to the same site(s) on the target. In practice,
the binding site(s) of the candidate ligand can be judged
based on its competitive binding against a reference
ligand but can not be optimized. (b) The candidate
ligand and its reference ligand, in both the PMFS and
the concentrated extract, produce peak areas within
their own linear ranges. (c) The candidate ligand and its
reference ligand, in both the PMFS and the concentrated
extract, produce peak areas over five times the absolute
values of their own intercepts of linear response. (d) The
candidate ligand and its reference ligand have binding
ratios of below 10% in the competitive binding system.
All the later three prerequisites should be met by opti-
mizing the experimental conditions.
For a pair of a candidate ligand and its reference
ligand in both the PMFS and the concentrated extract,
the satisfaction of the prerequisites of Eq.(6) for their
peak areas should be judged before assessing the satis-
faction of the prerequisites for their binding ratios. For
each ligand of interest, the intercept and the range of
linear response for assessing the satisfaction of prerequi-
sites of Eq.(6) can be indexed by the peak areas, and are
usually determined with the purified counterpart, but
such a purified counterpart is unavailable with a mix-
ture-based library. In practice, however, the intercept
and the linear range indexed by peak areas for each
ligand of interest can be estimated from the response of
its peak areas to the quantities of the PMFS; such para-
meters should be consistent with those obtained using a
purified counterpart, and can be used to judge the satis-
faction of the prerequisites of Eq.(6).
To use this new method for candidate ligand(s) of
unknown quantity in a mixture sample, the quantity of
the target used and the composition ratio of all ligands
of interest in a PMFS of the mixture sample are the
principal factors to be optimized. A parameter-depen-
dent or experimental approach can be used to estimate
an optimized quantity of the target, while a rough or
fine optimization way can be used to establish an opti-
mized PMFS composition ratio.
For estimating an optimized quantity of target, the
parameter-dependent approach requires some common
and individual parameters. The common parameters of
different mixture samples include the volumes of solu-
tions loaded for chromatographic analyses, the concen-
tration ratio and the binding capacity of the target. The
individual parameters for each ligand of interest in a
PMFS include its recovery ratio, its slope and intercept
of linear response by chromatographic analyses. The
slope of linear response of a candidate ligand can be
estimated from the response of its peak areas to the
quantities of the PMFS, and the content of the candi-
date ligand in its mixture sample prepared via PCS can
be approximated with information from databases such
as CASREACT http://www.cas.org/expertise/cascontent/
casreact.html. From such parameters, the minimum
quantity of target is calculated for a ligand of interest in
a concentrated extract to produce a peak area that
meets the prerequisites of Eq.(6) (additional file 1). The
sum of such minima of target required for all ligands of
the same binding site from a PMFS is an optimized
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of target that can be applied to different mixture sam-
ples is more desirable, but it cannot be reliably approxi-
mated due to the propagation of errors and competitive
binding among ligands from any PMFS.
For estimating an optimized quantity of target, the
experimental approach determines the response of peak
areas of each ligand of interest in the concentrated
extracts from a PMFS of a mixture sample to the quan-
tities of target used. From this response, a minimum
quantity of target for the peak area of each ligand of
interest in a concentrated extract to meet the prerequi-
sites of Eq.(6) is predicted. The maximum among such
minima of target for all ligands of interest from the
PMFS is an optimized quantity of target for the mixture
sample. A practical quantity of target that is reasonably
higher than such an optimized one estimated with a
representative mixture sample is expected to be applied
to different mixture samples.
The fine optimization way to establish an optimized
PMFS composition ratio involves the testing of a series of
the PMFSs whose concentrations of ligand(s) of interest
are increased stepwise. For any quantifiable candidate
ligand, the response of the relative affinities, which are
calculated via Eq.(6) without judging its validity, to
PMFS composition ratios is checked. Usually, the quanti-
ties of the mixture sample in PMFSs are increased step-
wise from a low initial value while the molar quantity of
the reference ligand in competitive binding systems is
fixed at a value where the binding ratio of the reference
ligand is about 10% in the absence of any other ligand.
For a candidate ligand whose affinity is much greater
than that of the reference ligand, the quantities of the
reference ligand in the PMFSs should be increased step-
wise from a low initial value while the quantity of the
mixture sample in the PMFSs is fixed. The reliable rela-
tive affinity of any candidate ligand is independent of its
concentrations in competitive binding systems. Thus,
during the stepwise adjustment of PMFS composition
ratios from a low initial value, relative affinities of any
quantifiable candidate ligand calculated via Eq.(6) with-
out judging its validity will become stable after Eq.(6) is
finally validated. The average, or any one, of the stable
relative affinities indexes the relative affinity of the candi-
date ligand, and any PMFS composition ratio to give
such a relative affinity of the candidate ligand is an opti-
mized one. An optimized PMFS composition ratio for a
candidate ligand may not necessarily apply to another
candidate ligand in the same mixture sample, and thus it
is hard to establish an optimized PMFS composition ratio
that can be applied to different mixture samples.
The rough optimization way to establish an opti-
mized PMFS composition ratio involves testing of just
a few PMFSs, in which the concentrations of ligand(s)
of interest are increased exponentially. With each
PMFS, the validity of Eq.(6) is judged for each pair of
a quantifiable candidate ligand and its reference ligand
before the preparation of the consecutive PMFS. The
concentration of a candidate ligand in its mixture sam-
ple, and parameters of linear response of ligands of
interest can be approximated as described just above.
In practice, in the first PMFS, the quantity of the mix-
ture sample is preset for binding ratio(s) of about 10%
for (most) candidate ligand(s) in the absence of the
reference ligand while the concentration of the refer-
ence ligand is preset at a value where its binding ratio
is about 10% in the absence of any candidate ligand. If
Eq.(6) is already validated for a pair of a candidate
ligand and the reference ligand with the first PMFS,
the relative affinity of the candidate ligand is available
and the composition ratio of the first PMFS is an opti-
mized one for the candidate ligand. Otherwise, the
contents of the mixture sample (or the concentrations
of the reference ligand) in the consecutive PMFSs are
increased exponentially until Eq.(6) is validated for the
pair of the candidate ligand and the reference ligand
(additional file 2). In general, the molar quantity of all
ligands of interest from the first PMFS should be con-
siderably large in the competitive binding systems to
validate Eq.(6) simultaneously for as many candidate
ligands as possible in the first PMFS, and the opti-
mized composition ratio of the first PMFS from a
representative mixture sample can be applied to differ-
ent mixture samples.
The sequential optimizations of experimental condi-
tions till Eq.(6) is validated for each pair of a quantifi-
able candidate ligand from a mixture sample and a
suitable reference ligand will ultimately give the relative
affinity of every quantifiable candidate ligand in the mix-
ture sample. The comparison of the relative affinities of
all candidate ligands from a library provides information
on valuable ligands. A candidate ligand bearing high
affinity to the desired binding site(s) on the target is a
hit from the library.
Design of experimental models
Experimental conditions can be easily optimized to vali-
date Eq.(6) for just one pair of a quantifiable candidate
ligand from a mixture sample and its reference ligand.
Therefore, this new method was firstly tested with each
mixture sample containing a single candidate ligand as
the primary component (the affinities of other com-
pounds as the secondary components are not estimated),
and then tested with each mixture sample containing
multiple candidate ligands.
To detect all biotin derivatives in a series of mixture
samples by HPLC-mass-spectrometry (HPLC-MS)
with just one exogenous reference ligand, some
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upon electro-spray-ionization (ESI) were designed,
including N-biotinyl-benzylamine (BBZA), N-biotinyl-
N’-(1-naphthyl)-ethylenediamine (BNEDA), methyl
biotin ester (BME), N-(Na-biotinyl-phenylalaninyl)-N’-
dansyl-ethylenediamine (BPDEDA), N-biotinyl-N’-dan-
syl-ethylenediamine (BDEDA), N-biotinyl-cyclohexyla-
mine (BCHA), N-biotinyl-diethanolamine (BDETA)
and N-biotinyl-morpholine (BMPL) [31,32] (additional
file 3 and additional file 4). Natural biotin which had
an e g l i g i b l es i g n a li nt h ep o s i t i v ei o nm o d ew a su s e d
as the reference ligand to judge the binding site(s) of
candidate ligands.
To prepare a single candidate biotin derivative in each
mixture via PCS without purification as a sample,
BCHA (cyclohexylamine is a primary alkyl amine),
BDETA (diethanolamine is a secondary alkyl amine),
BME (methanol is an alkyl alcohol) were used as poten-
tial specific candidate ligands, respectively, as large dif-
ferences in their yields were expected after limited
reaction periods with N-hydroxylsucciniimide biotin
ester (NHS-Biotin) [31,32].
To prepare multiple candidate ligands in mixture
samples, BCHA, BBZA, BNEDA and BDEDA were
used as potential specific candidate ligands. (1) To pre-
pare mixtures via the pooling of individual com-
pounds, N, N’-didansyl-ethylenediamine (DDEDA) and
di-(4-N-acetylaniline) methane (DNAM) were used as
the expected nonspecific candidate ligands of negligible
affinities, and they were pooled with potential specific
candidate biotin derivatives. (2) To prepare mixtures
via PCS, solution-phase simultaneous addition of
groups (SPSAG) was used [33]. In brief, a mixture of
some N-hydroxylsuccinamide esters including NHS-
Biotin was added to each mixture of some primary
alkyl amines in slight excess (Figure 2) [31,32]. Com-
parable reaction rates of primary alkyl amines with
NHS-Biotin support the postulation that the molar
quantity of each candidate biotin derivative in the
reaction mixture is determined by the molar quantity
of the corresponding alkyl primary amine. In these
mixtures via SPSAG, all the non-biotin components
with positive ion signals upon ESI were potential non-
specific candidate ligands (additional file 5). (3) To test
the universal applicability of the optimized conditions,
three mixture subtypes were prepared as defined
below. (a) Mixture A contained the four (expected)
candidate biotin derivatives (BCHA, BBZA, BNEDA
and BDEDA) with (expected) equal molar ratio; (b)
Mixture B contained (expected) BDEDA and BBZA at
the (expected) molar ratios of 1:3 and 3:1; (c) Mixture
C contained (expected) BNEDA and BCHA at the
(expected) molar ratios of 1:3 and 3:1.
Estimation of the affinity of a single candidate biotin
derivative in a mixture
HPLC-MS analyses of mixtures
Purified BMPL was used as the reference ligand for a
single candidate biotin derivative in each mixture sam-
ple. By using HPLC-MS via selective ion monitoring
(HPLC-MS-SIM) for M+H
+ of the biotin derivatives
(BMPL plus any one of BCHA, BDETA and BME),
some contaminants originating from SMPP with the
same m/z as the biotin derivatives were detected, but
the biotin derivatives of interest in any PMFS and those
in the concentrated extract could be readily resolved
from the contaminants (Figure 3 and 4). The use of
ethanolamine to remove residual NHS-Biotin produced
N-biotinyl-ethanolamine (m/z = 288 for M+H
+)i nt h e
designed mixture samples as a secondary component
whose affinity was not estimated.
The peak areas of each purified candidate biotin deri-
vative or BMPL responded linearly to the quantities
loaded for HPLC-MS-SIM analyses (Table 1, and addi-
tional file 6). The upper limit of the linear response for
any tested biotin derivative reached 30 pmol. BCHA had
the largest slope of linear response while BME gave the
smallest slope of linear response; the difference in their
slopes was 17-fold. The intercepts of linear response for
these purified biotin derivatives were all greater than
zero and had differences comparable to those in their
slopes.
Figure 2 SPSAG to prepare mixture samples of multiple biotin
derivatives.
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Page 6 of 18Figure 3 HPLC-MS-SIM analyses of a PMFS of BCHA alone as the ligand of interest. The PMFS of BCHA was prepared with purified BMPL
plus morpholine. N-biotinyl ethanolamine (BETA) was detected as a secondary ligand.
Figure 4 HPLC-MS-SIM analyses of the concentrated extractof bound ligands from the PMFS of BCHA alone as the ligand of interest.
The PMFS was that used in Figure 3. The component in the concentrated extract with m/z = 116 and a retention time of 1.4 min was a
contaminant from SMPP.
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content of each candidate biotin derivative in its reac-
tion mixture prepared via PCS was over 50%, with the
h i g h e s tc o n t e n tb e i n go v e r7 0 %f o rB D E T Aa n dt h e
lowest content being about 55% for BCHA. The peak
areas of each candidate biotin derivative and BMPL in
a PMFS also responded linearly to the quantities of the
PMFS loaded for HPLC-MS-SIM analyses. The differ-
ence in the intercepts of linear response for any puri-
fied candidate biotin derivative and its counterpart in
PMFS was below 20%, whereas the difference in the
linear ranges was negligible. However, the difference in
slopes for the purified BDETA and its counterpart in
PMFS was about 35%, which was the largest value
found.
Optimization of the quantity of SMPP and the
concentration ratio
The recovery ratio of each candidate biotin derivative
(BCHA, BDETA or BME), as well as that of BMPL, was
over 40% with a small coefficient of variation (CV), and
the relative recovery ratio of each candidate biotin deri-
vative to BMPL showed an even smaller CV (Table 1).
The highest sensitivity to quantify BCHA facilitated its
use to titrate the binding sites on SMPP, which was
about 4.2 nmol BCHA per mL SMPP. When 50 μL
SMPP was used in competitive binding systems and the
extracts of bound ligands were concentrated into 40 μL
methanol, HPLC-MS-SIM analyses of each biotin deri-
vative of interest (BCHA, BDETA, BME or BMPL) in
concentrated extracts confronted with negligible inter-
ference of contaminants from SMPP. When such
extracts were concentrated into 8 μL, however, some
contaminants with the same m/z caused interference
with HPLC-MS-SIM analyses of the biotin derivatives of
interest.
For establishing an optimized quantity of SMPP by the
parameter-dependent approach, the parameters of linear
response for each purified biotin derivative were used.
The minimum quantity of SMPP in a competitive bind-
ing system was estimated for each biotin derivative in
40 μL extract to produce a peak area over five times the
intercept of linear response. The sum of such SMPP
minima with a PMFS of each mixture sample was con-
sistently about 10 μL (Table 1, and additional file 1). For
the universal applicability to all designed mixture sam-
ples and the consideration of the potential binding of N-
biotinyl-ethanolamine, SMPP at 50 μL was used in each
competitive binding system of 2.0 mL and each extract
was concentrated into 40 μL methanol. This practical
quantity of SMPP was about four times the sum of the
SMPP minima estimated via the parameter-dependent
approach using linear responses by HPLC-MS-SIM ana-
lyses of purified biotin derivatives, but was over seven
times the sum of the SMPP minima estimated from
parameters of linear response with PMFSs (data not
given).
Optimization of PMFS composition ratios to estimate ligand
affinity
The fine optimization way was tested to establish an
optimized PMFS composition ratio. BMPL as the refer-
ence ligand in the competitive binding systems was
fixed at 1.0 μM for its binding ratio of about 10% in the
absence of other ligands. As calculated via Eq.(6) with-
out judging its validity, the relative affinities of each can-
didate biotin derivative (BCHA, BDETA, or BME)
gradually became stable during the stepwise adjustment
of PMFS composition ratios. (a) BCHA and BME have
higher affinities than BMPL. The peak areas of BCHA
or BME in concentrated extracts were usually five times
higher than the absolute value of the intercept of linear
Table 1 Parameters for HPLC-MS-SIM analyses and approximation of the minimum quantity of SMPP with each
mixture sample of a single candidate biotin derivative
Compound BCHA BMPL BDETA BME
m/z for M+H
+ 326 314 332 259
Slope for linear response
a 862.1 279.8 116.9 49.2
Intercept for linear response
a 322.1 143.4 59.9 24.2
R
2 for linear response > 0.998 > 0.998 >0.994 >0.992
Minimum quantity of the ligand in 5 μL solution to meet the prerequisites of Eq.(6) (pmol)
b 1.5 2.0 2.1 2.0
Minimum quantity of the ligand in 40 μL extract to meet the prerequisites of Eq.(6) (pmol) 12 16 16.8 16
Recovery ratio
c 0.47 1.00 0.57 0.82
Minimum quantity of the ligand bound to SMPP in competitive binding systems (pmol)
d 26 16 31.5 20
Minimal quantity of SMPP to bind the ligand (μL)
e 6.5 4.0 7.8 5.0
Summed minima of SMPP for a PMFS (μL) 11 - 12 9
aboth peak area and intercept were in μA.ms and the quantity of each pure biotin derivative was in pmol.
bcalculated as the quantity of the biotin derivative for peak areas five times of the absolute value of its intercept for linear response.
cdetermined in triplicate with variation coefficient below 9%.
dcalculated considering recovery ratio to give the required extract of bound ligand.
ecalculated with the binding capacity of 4 nmol per mL SMPP for a extract of equal contents of one candidate ligand and BMPL as the reference ligand.
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Page 8 of 18response. However, when the concentrations of BCHA
in its PMFSs were low, its binding ratios usually
exceeded 10%, and its relative affinities calculated via
Eq.(6) showed large positive deviations from those with
BCHA at higher concentrations in its PMFSs. The step-
wise increase in the concentrations of BCHA in the
PMFSs led to a continuous decrease in the binding
ratios, and its relative affinities calculated via Eq.(6) gra-
dually decreased to stable values after the binding ratios
of BCHA were below 10% (Figure 5). After this point,
any further increase in its concentrations in PMFSs
reduced the binding ratios but exerted few effects on its
relative affinities. Similar results were observed with
BME. (b) BDETA has a lower affinity than BMPL. The
binding ratios of BDETA were always below 10% while
its peak areas with concentrated extracts usually invali-
dated Eq.(6), when its concentrations in PMFSs were
relatively low. Similarly, the stepwise increase in BDETA
concentrations in PMFSs led to continuous decrease in
its binding ratios and its relative affinities finally
decreased to stable values after its peak areas with con-
centrated extracts were over five times its intercept of
linear response (Figure 6). (c) The average, or any one,
of the stable relative affinities of each candidate biotin
derivative (BCHA, BDETA, or BME) on the response
curve was taken as the index of its relative affinity, and
this relative affinity was consistent with that obtained
using a homogenous method and its purified counter-
part as the sample (Table 2) [32].
The rough optimization way to establish an optimized
PMFS composition ratio was also tested. When the con-
centration of BME (or BDETA) from its mixture sample
was equal to that of BMPL as the reference ligand in the
first PMFS, Eq.(6) was validated to give the relative affinity
that was consistent with that obtained by the fine optimi-
zation way. However, when the concentration of BCHA
from its mixture sample was equal to that of BMPL in the
first PMFS, the prerequisites for a validated Eq.(6) with
BCHA and BMPL were not met simultaneously. After the
concentration of BCHA from the mixture sample in the
second PMFS was increased by four-fold, all the prerequi-
sites to validate Eq.(6) were met concurrently, and the
relative affinity of BCHA was consistent with that obtained
by the fine optimization way (Table 2).
Estimation of affinities of multiple candidate biotin
derivatives in a mixture
HPLC-MS analyses of mixtures
BPDEDA was used as the exogenous reference ligand
for multiple candidate biotin derivatives in each mixture
sample. By HPLC-MS-SIM analysis of a PMFS from
Mixture A via the pooling of individual compounds, the
five biotin derivatives (BCHA, BBZA, BNEDA, BDEDA
and BPDEDA at equal concentrations) and other
Figure 5 Response curves of relative affinities and binding
ratios of BCHA to its concentrations in the competitive binding
systems containing 1.0 μM BMPL. *indicated significant difference
from the stable values after Eq.(6) was validated. Data were from
assays in duplicate with CVs of below 12%.
Figure 6 Response curves of relative affinities and binding
ratios of BDETA to its concentrations in the competitive
binding systems containing 1.0 μM BMPL. *indicated significant
difference from the stable value after Eq.(6) was validated. Data
were from assays in duplicate with CVs of below 10%.
Table 2 Relative affinity of a single candidate biotin
derivative in its mixture sample prepared via PCS
compounds Relative affinity Relatively affinity via Eq.(6)
Homogenous
method
Fine
optimization
a
Rough
optimization
b
BMPL 1.00 1.00
BCHA 3.68 ± 0.54 (5) 3.13 ± 0.27 (6) 3.23 ± 0.12 (2)
BME 1.90 ± 0.34 (2) 1.85 ± 0.25 (6) 1.65 ± 0.15 (2)
BDETA 0.45 ± 0.06 (4) 0.41 ± 0.11 (6) 0.51 ± 0.05 (2)
Number in parenthesis was for independent assays. For each candidate biotin
derivative, different methods yielded consistent relative affinities.
a The average of the stable relative affinities on the response curve.
b The result was from the second PMFS containing the approximated
candidate biotin derivative at 5.0 μM.
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Page 9 of 18detected components were readily resolved from each
other. Peak areas of each detected component in this
PMFS responded linearly to the quantities of the PMFS
loaded for HPLC-MS-SIM analyses (additional file 7).
The intercept of linear response for BBZA was below
zero while those of the other biotin derivatives were
over zero. The slope of linear response for BCHA was
comparable to that for BDEDA and was higher than
those for other biotin derivatives, but the slope of linear
response for BNEDA was the lowest among those for
the five biotin derivatives.
Optimization of the quantity of the target and PMFS
composition ratios
In the 40 μL concentrated extract from a competitive
binding system containing 0.20 mL SMPP and the
PMFS of Mixture A via the pooling of individual com-
pounds, each bound biotin derivative was resolved from
other components (additional file 8). The recovery ratios
of DNAM and DDEDA were over 35% while those of
the five biotin derivatives in the PMFS of Mixture A
were consistently over 40%.
The parameter-dependent approach was tried at first to
estimate an optimized quantity of SMPP using linear
responses from HPLC-MS-SIM analyses of a PMFS of
Mixture A, which served as the representative mixture
because its number of candidate ligands was the largest.
The sum of the minimum quantities of SMPP was about
13 μL, for all the five biotin derivatives from the PMFS to
have peak areas over five times their own intercepts of
linear response (additional file 9). This sum of SMPP
minima must have large errors, as it was just comparable
to that estimated by the same approach for a mixture of
a single candidate biotin derivative (Table 1).
With a representative mixture, an optimized quantity
of SMPP was then estimated by the experimental
approach and meanwhile optimized PMFS composition
ratios were sought. Among the designed biotin deriva-
tives, BNEDA had the highest affinity while BBZA had
the lowest affinity (Table 3). Two mixtures of BNEDA
and BBZA were thus prepared via SPSAG using the two
mixtures of BZA and NEDA at molar ratios of 1:6 and
6:1, respectively, and were used as the representative
mixtures. The following results were obtained with
these two representatives. (a) With a PMFS of the mix-
ture via SPSAG using NEDA and BZA at 1:6, the
expected total concentration of all candidate biotin deri-
vatives was firstly preset at about 4.6 μMa n dt h ef i n a l
BPDEDA concentration was preset at 2.0 μM in compe-
titive binding systems. In this case, peak areas for each
bound biotin derivative in the concentrated extracts
(Figure 7), and binding ratios of each biotin derivative
(Figure 8), responded linearly to the quantities of SMPP
used. As predicted from these responses, Eq.(6) was vali-
dated for BBZA and BPDEDA with a minimum quantity
of SMPP of just 0.05 mL, but was validated for BNEDA
and BPDEDA with a minimum quantity of SMPP of
over 0.15 mL. (b) In competitive binding systems con-
taining 0.20 mL SMPP, the binding ratios of BBZA and
BNEDA were simultaneously reduced to below 10%
when the expected total concentration of the three bio-
tin derivatives was increased to over 11.0 μM (Figure 9).
However, when the final BPDEDA concentration in
competitive binding systems was fixed at 2.0 μM, the
binding ratios of all the biotin derivatives were reduced
to below 10% when the expected total concentration
of the biotin derivatives was slightly over 8.0 μM
(Figure 10). Thus, the optimization of PMFS composi-
tion ratios, rather the quantities of a PMFS alone, was
more efficient to validate Eq.(6). (c) A PMFS of the
other mixture prepared using NEDA and BZA at 6:1
was tested in the competitive binding systems contain-
ing 0.20 mL SMPP and BPDEDA at 4.0 μM. Peak areas
of BBZA and BPDEDA in the concentrated extracts
invalidated Eq.(6) even if the expected total molar con-
centration of the biotin derivatives was over 40 μM, but
the peak areas of BNEDA were always sufficiently high
to meet the prerequisites of Eq.(6). If the quantities of
SMPP were over 0.60 mL, Eq.(6) was simultaneously
validated for BBZA, BNEDA and BPDEDA when the
expected total concentration of the candidate biotin
derivatives was over 16.0 μM and the final BPDEDA
concentration was 4.0 μM. Therefore, for any candidate
ligand possessing both a lower affinity and a lower con-
centration in a mixture sample, there was the need of
more time and cost for optimizing conditions to esti-
mate its affinities. (d) Taken together, in each
Table 3 Relative affinities of multiple candidate biotin derivatives in mixture samples prepared via the pooling of
individual compounds and SPASG
Mixtures Compound BDEDA BBZA BCHA BNEDA n
Mixture KX/KA KX/KA KX/KA KX/KA
Pooling individual compounds Mixture A 1.4 ± 0.2 0.6 ± 0.2 1.4 ± 0.2 2.0 ± 0.5 4
Mixture B or C 1.3 ± 0.2 0.7 ± 0.3 1.4 ± 0.4 2.1 ± 0.6 6
Combinatorial syntheses Mixture A 1.1 ± 0.3 0.6 ± 0.3 1.4 ± 0.5 2.1 ± 0.6 4
Mixture B or C 1.1 ± 0.2 0.5 ± 0.1 1.2 ± 0.3 1.9 ± 0.4 6
Homogenous methods Pure compound 1.3 ± 0.1 0.6 ± 0.1 1.3 ± 0.1 2.0 ± 0.2 2
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Page 10 of 18competitive binding system, 0.20 mL SMPP was used,
the final BPDEDA concentration was fixed at 2.0 μM
and the expected total molar concentration of all candi-
date biotin derivatives was over 4.6 μM from the first
PMFS of any mixture sample. This practical quantity of
SMPP was just slightly higher than that estimated by
the experimental approach with a PMFS of a representa-
tive mixture, but was over sixteen times that estimated
by the parameter-dependent approach with Mixture A
via the pooling of individual compounds (additional file
9). The total molar quantity of the biotin derivatives
from the first PMFS was nearly thirty times the molar
quantity of SMPP used, and may be universally applied
to mixture samples.
Estimation of affinities of multiple ligands in mixtures via
the pooling of individual compounds
Under the aforementioned optimized conditions, the
binding ratios of DNAM and DDEDA from the PMFS
of Mixture A via the pooling of individual compounds
Figure 7 Effects of SMPP quantities on ratios of the peak areas
of each biotin derivative to the absolute value of its intercept
of linear response with a PMFS of a mixture of BNEDA and
BBZA prepared via SPSAG using NEDA and BZA at 1:6 ratio.
Final BPDEDA was 2.0 μM and the expected total concentration of
the two candidate biotin derivatives was 4.6 μM.
Figure 8 Effects of SMPP quantities on the binding ratios of
each biotin derivative from the PMFS of the mixture of BNEDA
and BBZA prepared via SPSAG using NEDA and BZA at 1:6
ratio. Conditions were completely the same as those described in
Figure 7.
Figure 9 Effects of the quantities of a PMFS on the ratios of
peak areas of each biotin derivative to the absolute value of
its intercept of linear response. The PMFS was that used in Figure
7. SMPP of 0.20 mL was used in the competitive binding systems.
Figure 10 Effects of the composition ratios of the PMFSs on
the ratios of peak areas of each biotin derivative to the
absolute value of its intercept of linear response. The quantity
of SMPP was 0.20 mL. The composition ratios of the PMFSs were
adjusted by keeping the final BPDEDA at 2.0 μM in the competitive
binding systems.
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Page 11 of 18were usually below one-eighth that of BBZA in the
competitive binding systems. In the presence of 40 μM
biotin in a competitive binding system, the binding ratio
of each biotin derivative from the PMFS of Mixture A
was reduced by over 40%, whereas those of DNAM and
DDEDA showed negligible changes (additional file 8).
To the denatured SMPP, all the tested biotin derivatives
showed undetectable binding, whereas DNAM and
DDEDA showed unchanged binding. Therefore, DNAM
and DDEDA in Mixture A are weak nonspecific ligands.
Using the aforementioned optimized conditions, Eq.(6)
was validated for each biotin derivative with the PMFS
of Mixture A via the pooling of individual compounds.
No outliers were found in the relative affinity of each
candidate biotin derivative from Mixture A [34], and the
affinity ranking was BNEDA > BCHA ≈ BDEDA >
BBZA. The relative affinities of these biotin derivatives
were consistent with those estimated by a homogenous
method using their purified counterparts as samples
(Table 3) [32]. With the PMFSs of Mixtures B and C,
Eq.(6) was validated under the optimized conditions.
The relative affinity of each candidate biotin derivative
in Mixtures B and C had no outliers and was consistent
with that in Mixture A. Consistent relative affinities for
the two candidate biotin derivatives in Mixtures B and
C via the pooling of individual compounds were
o b t a i n e de v e nw h e nt h e i rm o l a rr a t i o sw e r e1 : 6o r6 : 1 .
There were consistent results when an Agilent 1100
LC-MS system was used to analyze the same mixtures,
or when the quantification sensitivity of the HPLC-MS
system in use was reduced by 90% (data not given);
these results supported the robustness of this method.
Estimation of affinities of multiple ligands in mixtures via
SPSAG
The five biotin derivatives in the PMFS from Mixture A
prepared via SPSAG were reliably quantified by HPLC-
MS-SIM, meanwhile only some of the expected non-biotin
derivatives were quantifiable under the same conditions
(Figure 11). With the PMFS of Mixture A prepared via
SPSAG, peak areas of each detected component responded
linearly to the quantities of the PMFS with the intercept
slightly over zero. Mixture A had approximately equal
concentrations of the four candidate biotin derivatives and
the total content of the biotin derivatives by mass weight
accounted for over 80% of the mixture. The molar ratios
of BDEDA and BBZA in Mixture B were found to be
about 3.0:1 and 1:3.8 while the molar ratios of BNEDA
and BCHA in Mixture C were found to be about 2.6:1 and
1:3.6. In Mixtures B and C, the total content of the biotin
derivatives by mass weight was slightly over 60% of the
mixture.
The average of recovery ratios of all the quantifiable
non-biotin components in the PMFS from Mixture A
via SPSAG was over 30%, with CVs of about 25% (n =
3). Among the quantifiable components, only the
expected biotin derivatives showed the obvious binding
to SMPP (Figure 12). In the presence of 40 μM biotin in
a competitive binding system containing the PMFS of
Mixture A via SPSAG, the binding ratios of the five bio-
tin derivatives were all reduced by over 35%. No compo-
nents in this PMFS showed detectable binding to SMPP
denatured by heating in methanol. Therefore, quantifi-
able components other than biotin derivatives in the
mixtures prepared via SPSAG were also not ligands of
SMPP.
With the PMFS of Mixture A via SPSAG under the
optimized conditions, Eq.(6) was validated for each candi-
date biotin derivative. The relative affinity for each of the
four candidate biotin derivatives had no outliers but had
the desirable consistency with that from Mixture A via the
pooling of individual compounds. With Mixtures B and C,
the consistent relative affinity for each of the four candi-
date biotin derivatives was also obtained (Table 3).
Discussion
To practice this new method with mixture samples, its
feasibility and reliability, its overall cost and efficiency,
are primarily concerned. Therefore, as for candidate
ligands in such mixture samples, their numbers and the
differences in their molar quantities should be con-
trolled within reasonable ranges; the experimental con-
ditions should be carefully optimized.
For the feasibility of this new method, a pair of a
reference ligand and a candidate ligand should be con-
currently quantified in both a PMFS and its concen-
trated extract by a chromatographic system of high
resolution, such as HPLC-MS [35,36]. For any mixture
sample of multiple candidate ligands, a preferable refer-
ence ligand should have an affinity close to the medium
of the affinities of all candidate ligands in the mixture
sample so that it can be simultaneously quantified with
as many candidate ligands as possible in the concen-
trated extracts. It is laborious to optimize experimental
conditions till Eq.(6) is validated for each pair of a quan-
tifiable candidate ligand from a mixture sample and a
suitable reference ligand, when candidate ligands in
such a mixture sample have a large number or large dif-
ferences in their quantities. Hence, this new method is
practical for a mixture sample containing a limited
number of candidate ligands whose molar quantities
have moderate differences, and any candidate ligand
whose affinity is lower than a quantified one of any
other candidate ligand in the same mixture sample can
be abandoned. In practice, a mixture of a single candi-
date ligand or a racemic mixture of a few pairs of enan-
tiomers can be prepared via PCS without purification as
a sample for screening by this new method, as long as
the overall cost and efficiency are favorable.
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Page 12 of 18For the reliability of this method, all the prerequisites
of Eq.(6) should be concomitantly met for a pair of a
quantifiable candidate ligand and its reference ligand. In
appearance, the concentration ratio, the quantity of the
target and that of a PMFS used in competitive binding
systems, can be as large as possible to facilitate validat-
ing Eq.(6). However, competitive binding among ligands
of interest from any PMFS and nonspecific binding of
ligands of interest at higher concentrations require the
optimizations of both the composition ratio of the
PMFS and the quantity of the PMFS in the competitive
binding system. The cost of the target also requires the
optimization of the quantity of the target used. At
higher concentration ratios, the potential interference
from contaminants in the target with chromatographic
analyses of ligands of interest becomes more significant
and there may be precipitates of some ligands of interest
from the extract. In fact, the maximum concentration
ratios are primarily restricted by the quantities of
contaminants of interference from the target, and thus
indirectly determined by the quantity of the target used,
after the optimization of the solvent(s) to enhance the
solubility of ligands of interest. Hence, the composition
ratio of ligands of interest in a PMFS, the quantity of
the PMFS and that of the target used in competitive
binding systems, all should be carefully optimized.
To estimate an optimized quantity of the target, the
parameter-dependent approach is simple because it only
requires the individual chromatographic parameters of
linear response and the individual recovery ratios of all
ligands of interest from a PMFS, besides some common
parameters (additional file 1). But this approach suffers
from large uncertainty due to error propagation, which is
more pronounced with mixtures of multiple candidate
ligands (additional file 9). In the experimental approach,
a representative mixture sample possessing candidate
ligands with moderate differences in both their quantities
and affinities is needed, and the practical quantity of the
Figure 11 HPLC-MS-SIM analyses of a PMFS of Mixture A prepared via SPSAG. Only some typical components were monitored during
HPLC-MS-SIM analyses. The component with m/z = 356 around 7.0 min was a contaminant in SMPP, and those with m/z = 290 around 4.0 min
and m/z = 484 around 7.0 min were expected nonspecific components (additional file 5).
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Page 13 of 18target can be slightly higher than an optimized one to
enhance universal applicability to different mixture sam-
ples. Hence, the experimental approach is preferable, and
this assertion was supported by experimental results.
Due to the unknown quantity(ies) of candidate ligand
(s) in each mixture sample, PMFS composition ratios
have to be carefully optimized. For favorable efficiency in
the optimization of PMFS composition ratios, the con-
centration of a reference ligand (or the content of a mix-
ture sample) in the PMFSs, together with the quantities
of the PMFSs in the competitive binding systems, can be
fixed so that only the contents of the mixture (or the
concentrations of the reference ligand) in the PMFSs
need to be optimized. The fine optimization way relies
on stepwise adjustment of PMFS composition ratios, and
the appearance of stable relative affinities of a candidate
ligand in each mixture sample is required. Therefore, the
fine optimization way suffers from the unfavorable cost
and time involved with seeking optimized PMFS compo-
sition ratios for different mixture samples. On the other
hand, the rough optimization way adjusts PMFS compo-
sition ratios exponentially (Table 2 and 3), and requires
the range and intercept of linear response of each ligand
of interest to judge the validity of Eq.(6). These required
parameters can be easily obtained by chromatographic
analyses of a PMFS, as supported by experimentation.
More importantly, optimized composition ratios of the
first PMFSs can be applied to different mixture samples.
Hence, the rough optimization way is preferable.
Under optimized conditions, two candidate biotin deri-
vatives whose affinities were different by 50% were discri-
minated (Table 2 and 3). Large systematic errors in
quantification sensitivity impacted negatively on neither
the reliability of ligand affinities nor the universal applic-
ability of optimized conditions. In Eq.(6), only
RRA
RRX
,
ATX
ATA
and
ABX
ABA
are required. There is a close covariance among
the quantities of components by chromatographic analyses
of a PMFS or its concentrated extract, and thus the propa-
gation of errors from peak areas and recovery ratios into
the relative affinity of a candidate ligand is greatly reduced
[34]. Hence, the use of a PMFS of each mixture sample
accounts primarily for the robustness of this method.
Conclusions
Taken together, the following conclusions can be drawn.
(1) This method is effective and robust for mixture
samples possessing a limited number of candidate
Figure 12 HPLC-MS-SIM analyses of the concentrated extract from the PMFS of Mixture A prepared via SPSAG. The PMFS was exactly
that used in Figure 11.
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Page 14 of 18ligands whose molar quantities have moderate
differences.
(2) This method is effective for candidate ligands of
high affinities in mixture samples, as evidenced by
the tested biotin derivatives with dissociation con-
stants below 200 fM [31,32].
(3) This method has favorable cost and efficiency for
screening candidate ligands of unknown quantity in
mixture samples. It only requires standard chroma-
tographic systems and the optimized conditions are
generally applicable to most mixture samples from a
library.
(4) The integration of PCS with this new method is
practical to realize the mixture-based combinatorial
library strategy with the desirable overall efficiency
and cost.
Methods
Materials and chemicals
Streptavidin and SMPP, streptavidin MagneSphere™
paramagnetic particles, were from Promega. N-(1-
naphthylene)-ethylenediamine (NEDA), cyclohexylamine
(CHA), N-hydroxysuccinimide (NHS), ethylenediamine
(EDA), dicyclohexylcarbodiimide (DCC), diethanolamine
(DETA), dansyl chloride (DNS-Cl), morpholine (MPL),
and N-t-Boc-L-phenylalanine were from Alfa Aesar. D-
Biotin (purity > 99%) was from BIO BASIC INC (USA).
Benzylamine (BZA) and all other chemicals were
reagents of analytic grade or above, and solvents were
re-stilled under reduced pressure before use.
Instruments
Captivate™ magnetic separator (C24703) was from
Molecular Probes. A Shimadzu 2010 liquid chromato-
graphy system equipped with a 5 μL injector and a
2010A mass spectrometer detector was used. Other
instruments were those we used before [31,32].
Syntheses of individual biotin derivatives
N-dansyl-ethylenediamine (DEDA) was prepared as
before [32]. N-phenylalaninyl-N’-dansyl-ethylenediamine
(PDEDA) was prepared by condensation of DEDA and
N-t-Boc-phenylalanine, and was purified via chromato-
graphy after deprotection. NHS-Biotin was prepared as
before [31]. Reaction of NHS-Biotin with PDEDA in
excess in dichloromethane at room temperature in dark
for 24 h yielded BPDEDA that was confirmed by NMR
and high-resolution mass-spectrometry. Other biotin
derivatives were prepared as before [31,32].
Mixture of a single candidate ligand prepared via PCS
Each mixture of purified NHS-Biotin plus CHA or
DETA (1:1.1) in chloroform was kept at room tempera-
ture for 6 h. Meanwhile, NHS-Biotin was kept in
methanol for 18 h at room temperature. Then, ethanola-
mine in large molar excess to NHS-Biotin was added to
each mixture for reaction of 3 h at room temperature to
remove residual NHS-Biotin via the production of N-
biotinyl ethanolamine. After the removal of solvents at
40°C, biotin derivatives in each mixture were precipi-
tated and washed with ethyl ether. The dried residual
served as a mixture sample of a single candidate ligand.
The mass content of each candidate biotin derivative in
its mixture sample was arbitrarily taken as 50%, unless
otherwise stated.
Mixture of multiple candidate ligands prepared via the
pooling of individual compounds
DEDA was further dansylated in chloroform to give
DDEDA that was roughly purified by repetitive wash
with 0.1% HCl and water. DNAM was prepared with
bis-(4-aniline)-methane and acetyl anhydride in dichlor-
omethane, followed by repetitive wash with 1% NaOH,
1% HCl and then water. DNAM and DDEDA were pre-
mixed at equal molar concentrations, and were further
mixed with the indicated candidate biotin derivatives to
prepare Mixture A, B and C in methanol, for the aver-
age of molar quantities of biotin derivatives equal to
that of DDEDA.
Mixture of multiple candidate ligands prepared via SPSAG
2-Hydroxyethyl benzoate was prepared with ethylene
glycol and benzoyl anhydride (50:1) in chloroform, fol-
lowed by repetitive wash with 1% NaOH and water. 2-
Hydroxyethyl benzoate, BZA, cyclopentanol and benzy-
lalcohol were then mixed at approximately equal molar
concentrations in chloroform, to which was added succi-
nic anhydride (1.05 molar quantity of nuleophiles in
total, reflux for 6 h). Then, NHS (1.05 molar quantity of
succinic anhydride) and DCC were added (reflux for 12
h) to activate carboxylic acids. After the removal of the
precipitates and most solvents, reactive esters in the
solution were titrated with NEDA (detected by TLC),
and were mixed with NHS-Biotin to make a new mix-
ture of reactive esters (the molar quantity of NHS-Biotin
was about one quarter of the total molar quantity of
other reactive esters). Meanwhile, three mixtures of the
required alkyl primary amines were prepared via the
pooling of individual compounds, and were used in
slight excess to react with the aforementioned new mix-
ture of reactive esters in chloroform to produce Mix-
tures A, B and C, respectively (Figure 2). Solvents in
each reaction mixture were removed under reduced
pressure to give a residual that served as a mixture sam-
ple after the wash with ethyl ether (additional file 5).
Other mixtures were prepared similarly. It was assumed
that the total mass content of biotin derivatives was 40%
of each mixture and the molar quantity of each biotin
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corresponding alkyl primary amine.
Affinity estimation by this new method
Tris-HCl buffer (0.03 M, pH 7.0) was used throughout.
Each PMFS was made by mixing a mixture sample at an
indicated quantity with its exogenous reference ligand
(BMPL or BPDEDA) at a fixed quantity, both in metha-
n o l ,t oh a v eaf i n a lr e f e r e n c el i g a n da t2 0 0μM in each
PMFS. With any mixture of a single candidate ligand,
each competitive binding system in 2.0 mL contained 50
μLS M P P( w a s h e dw i t ht h eb u f f e r )a n dad i l u t e dP M F S
at 40 μL. With any mixture of multiple candidate
ligands, each competitive binding system in 4.0 mL con-
tained 200 μL SMPP and a PMFS at 40 μL. With a mix-
ture of multiple candidate biotin derivatives, the
(expected) total molar quantity of candidate biotin deri-
vatives in competitive binding systems was over 4.6 μM,
unless stated otherwise. Each competitive binding sys-
tem was kept at 25°C for 25 min with gentle shaking at
5-s intervals. Then, target-ligand complexes were recov-
ered via magnetic force to extract bound ligands with
1.0 mL methanol at 45°C for 30 min. Each extract was
filtered through 0.22 μm membrane; solvents were
removed at 40°C to give residuals that were dissolved in
40 μL methanol to serve as the concentrated extract.
Each PMFS and its concentrated extract were analyzed,
in duplicate, by HPLC-MS-SIM under identical condi-
tions. SMPP were heated in methanol at 50°C for 50
min to detect potential nonspecific binding.
HPLC-MS-SIM analyses
Phenomenex Gemini 3 μ C18 reversed-phase column
(10.0 cm × 0.2 cm) was used, and column temperature
was maintained at 25°C. The mobile phase was 55%
methanol plus 45% aqueous acetic acid (0.3% acetic acid
in water) and was used at 0.20 mL per min. M+H
+ of
each compound upon ESI was monitored. The standard
nebulized ESI was carried out with the capillary at 3.5
kV, detector at 1.4 kV and curve desolvation line tem-
perature at 250°C. Each time, 5.0 μLs o l u t i o nw a s
injected for analysis. Each biotin derivative in mixture
was identified from its m/z for M+H
+, retention time,
isotope abundance and co-chromatography with its pur-
ified counterpart. Each PMFS and its extract of bound
ligands were analyzed consecutively.
Determination of recovery ratio
A mixture of a purified candidate biotin derivative and
its reference ligand (BMPL or BPDEDA) at equal molar
quantities was added to Tris-HCl buffer in 2.0 mL con-
taining 400 μL SMPP for the total binding capacity of
over 1.6 nmol, and each biotin derivative of interest had
the final level of 0.2 μM. Other operations were the
same as those for affinity estimation and concentrations
of biotin derivatives were determined by HPLC-MS-
SIM. Peak areas of each biotin derivative of interest, in
both the PMFS and its concentrated extract of bound
ligand, were kept over five times the absolute value of
its intercept of linear response but within its linear
range by proper dilution. Recovery ratio was the percen-
tage of the peak area of a biotin derivative in its concen-
trated extract to that in the binding mixture minus
SMPP after the concentration effect was corrected. Rela-
tive recovery ratio was the percentage of the recovery
ratio of a candidate biotin derivative to its reference
ligand. Recovery ratio of a non-biotin component was
its conservation percentage after being heated at 45°C in
methanol for 30 min.
Homogenous competitive assay of affinity
With tryptophan residues in streptavidin as intrinsic
donors while fluorescent biotin derivatives as the för-
ster-resonance-energy-transfer acceptor, the homoge-
nous competitive assay of affinity was realized by
monitoring streptavidin fluorescence at 340 nm as
before [32].
Data processing and statistic analyses
Relative affinity was calculated from peak areas via Eq.
(6). Data were the mean ± standard deviation. Student’s
t-test was used to compare differences with P <0 . 0 5a s
the confidence limit.
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